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Abstract 
The fibroblast growth factor receptor 4 (FGFR4) is thought to be involved in many critical 
cellular processes and has been associated with prostate cancer risk.  Four single nucleotide 
polymorphisms within or near FGFR4 were analysed in a population-based study of 1458 
prostate cancer patients and 1352 age-matched controls.  We found no evidence to suggest that 
any of the FGFR4 SNP genotypes were associated with prostate cancer risk or with disease 
aggressiveness, Gleason score or stage.  A weak association was seen between rs351855 and 
prostate cancer-specific mortality.  Subset analysis of cases that had undergone radical 
prostatectomy revealed an association between rs351855 and prostate cancer risk.  While our 
results confirm an association between FGFR4 and prostate cancer risk in radical prostatectomy 
cases, they suggest that the role of FGFR4 in disease risk and outcomes at a population-based 
level appears to be minor. 
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Introduction 
FGFR4 belongs to a family of four transmembrane tyrosine kinase receptors (FGFR1-4) and is 
activated by several members of the fibroblast growth factor (FGF) family coupled with an 
accessory molecule of heparin sulfate proteoglycan (1,2).  FGFRs are thought to play a role in 
critical cellular processes including cell cycle regulation, migration, metabolism, survival, and 
cellular proliferation and differentiation (2).  Activation of the extracellular domain of FGFRs 
leads to intracellular signaling of multiple signal transduction pathways including the Erk, 
MAPK, PI3K-Akt pathways and WNT pathways, which are thought to be involved in cancer onset 
and progression (3,4). 
 FGFs and FGFRs have been associated with the occurrence and prognoses of many types 
of cancer including that of the prostate, breast and lung (3-16).  Findings suggest that rs351855, a 
missense change at codon 388 (Gly388Arg) in the transmembrane domain of the FGFR4 gene, 
could play a role in tumorigenesis and disease progression of these cancers (15-21).  In the case 
of prostate cancer, FGFR4 was found to be associated with disease occurrence, tumor 
proliferation, and aggression (13,15,16).  Wang and colleagues (2004) genotyped rs351855 in 
329 cases who underwent radical prostatectomy and 191 controls and found a significant 
association between the Arg allele and prostate cancer occurrence, pelvic lymph node metastasis, 
and prostate-specific antigen (PSA) recurrence in Caucasians (16).  Additional evidence to 
suggest a role in prostate cancer has come from protein expression and cell culture studies.  
FGFR4 expression is elevated in tumor epithelial cells as compared to normal epithelium (13,16) 
and cells expressing the Gly allele of rs351855 grow in tighter colonies, show a slower closure 
rate in wound assays, and are less invasive in Matrigel than Arg expressing cells (16).   
In spite of the numerous genetic studies analyzing associations between variants in 
FGFR4 and cancer, only one non-synonymous SNP (rs351855) has been genotyped in these 
studies.  In addition, many of these studies were performed on a small number of samples and in 
selected populations.  To address these issues we analyzed four tag SNPs, including rs351855 
and two other non-synonymous SNPs, in and near the FGFR4 gene in 1458 men with prostate 
cancer and 1352 age-matched controls from a population-based case-control study.  
 
Materials and methods 
The study population consists of participants from two population-based case-control studies of 
prostate cancer in Caucasian and African American residents of King County, Washington 
(Study I and Study II), whose collection methodologies have been previously described (22,23).  
Incident cases with histologically confirmed prostate cancer were ascertained from the Seattle-
Puget Sound SEER cancer registry.  In Study I, cases were diagnosed between January 1, 1993, 
and December 31, 1996 and were 40-64 years of age at diagnosis.  In Study II, cases were 
diagnosed between January 1, 2002, and December 31, 2005 and were 35-74 years of age at 
diagnosis.  Overall, 2,244 eligible prostate cancer patients were identified and 1,754 (78.2%) 
were interviewed.  The main reasons for non-response were patient refusal (13.9%), physician 
refusal to allow patient contact (2.1%), patients were too ill to participate (0.9%), or died before 
interview (1.4%).  Blood samples yielding sufficient DNA for genotyping were drawn from 
1,457 (83.1%) cases who completed the study interview.  
 A comparison group of controls without a self-reported history of prostate cancer, 
residing in King County, Washington, was identified using random digit dialing (RDD).  
Controls were frequency matched to cases by five-year age groups and recruited evenly 
throughout each ascertainment period for cases.  During the first step of RDD, complete 
household census information was obtained for 94% and 81% of the residential telephone 
numbers contacted for Study I and Study II, respectively.  A total of 2,448 men were identified 
who met the eligibility criteria and 1,645 (71.7%) completed a study interview.  The main 
reasons for non-participation included refusal (29.1%) or too ill to participate (1.4%).  Blood 
samples were drawn and DNA prepared from 1,352 (82.2%) interviewed controls using standard 
protocols. 
 Subjects in both studies completed in-person interviews conducted by trained male 
interviewers using standardized questionnaires.  The questions pertained to the time period up to 
the reference date, i.e., the date of prostate cancer diagnosis for cases and a randomly pre-
assigned date for controls that approximated the distribution of cases' diagnosis dates.  
Information was collected on family structure and cancer history, medical history, and social and 
demographic factors.  Clinical information on cases, including Gleason score, tumor stage, serum 
PSA level at diagnosis and primary treatment, was obtained from the SEER cancer registry.  All 
study procedures were approved by the Fred Hutchinson Cancer Research Center institutional 
review board and the National Human Genome Research Institute.  Written informed consent 
was obtained from all study participants prior to participation.  
The Genome Variation Server (http://gvs.gs.washinton.edu/GVS/) was utilized to select 
FGFR4 tag SNPs.  Only data from the HapMap CEU population were screened with analysis 
parameters set as a minor allele frequency of 5% or higher and an r2 threshold of 0.80.    A total 
of four SNPs were selected for analysis:  rs1966265 (Ile10Val), rs376618 (Leu136Pro), rs351855 
(Gly388Arg) and rs7708357.  The former three are coding non-synonymous SNPs within 
FGFR4, while rs7708357 is situated 3’ of the gene and was selected to distinguish the six 
haplotypes that occur in the LD block spanning FGFR4. 
 The Applied Biosystems (ABI) SNPlex™ Genotyping System was used to genotype the 
SNPs and proprietary GeneMapper® software was used for allele calling 
(www.appliedbiosystems.com).  Discrimination of the specific SNP allele was carried out on the 
ABI 3730xl DNA Analyzer and is based on the presence of a unique sequence assigned to the 
original allele-specific oligonucleotide.  Quality control included genotyping of 140 blind 
duplicate samples distributed across all genotyping batches.  There was 100% agreement 
between the blinded samples for each of the four SNPs.  Each 384-well batch of DNA aliquots 
genotyped incorporated similar numbers of case and control samples, and all laboratory 
personnel were blinded to the case-control status of samples. 
Departure from Hardy-Weinberg equilibrium was assessed for each SNP separately in 
controls using the allele procedure in SAS version 9.1.3.  Pairwise linkage disequilibrium (LD) 
was estimated between SNPs based on the r2 statistic calculated in controls, using Haploview 
software version 4.0 (http://www.broad.mit.edu/mpg/haploview/). 
Unconditional logistic regression models were used to estimate odds ratios (OR) and 95% 
confidence intervals (95% CI) to measure the association between individual SNP genotypes and 
prostate cancer risk (24), as implemented in SAS version 9.1.3.  Potential confounding factors, 
including age at reference date, PC screening history and first-degree family history of prostate 
cancer, were examined to see if such factors changed the risk estimates by ≥ 10%.  After these 
tests, only age at reference date was included in the final models.  Polytomous regression models 
were used to generate ORs and 95% CIs for the association between SNP genotypes and cases 
with prostate cancer stratified by disease aggressiveness (less versus more), Gleason score {≤7 
(3+4) versus  ≥ 7 (4+3)}, and tumor stage (local versus regional/distant) compared to controls.  
More aggressive cases were those with either a Gleason score of ≥ 7 (4+3), regional or distant 
stage disease, or a PSA level ≥ 20 ng/mL at diagnosis. Both codominant (additive) and dominant 
genetic models were considered for each variant allele, depending on the distribution of 
genotypes.   
A permutation procedure was used to account for the effect of multiple testing. Pairs of 
case-control labels and ages were permuted in order to approximate the distribution of the age-
adjusted p-values under the null hypothesis.  Ages and case-control labels were permuted 
together to preserve any relationship that may exist between age and case-control status and 
allow age-adjusted p-values to be calculated for each permutation that are consistent with the 
original analysis.  For each permutation, codominant and dominant models were fit for all SNPs 
and the minimum of the p-values kept for each SNP.  The p-values were ordered to approximate 
the null distribution of the order statistics for the p-values, i.e., minimum p-value, second 
smallest p-value, etc.  The original p-values were also ordered and permutation p-values were 
calculated by comparing the ordered p-values to the null distribution for the appropriate order 
statistic. Permutation p-values can be interpreted as the probability of observing a p-value less 
than or equal to what was observed for the given order statistic under the null hypothesis of no 
association with disease for any of the 4 SNPs.  For example, the minimum p-value was 
compared to the null distribution for the minimum p-value and the corresponding permuted p-
value can be interpreted as the probability of the minimum p-value being less than or equal to the 
observed minimum p-value under the null hypothesis.  The same is true for the second smallest 
p-value, the third smallest p-value, etc.  The permutation approach to approximating the null 
distribution of the order statistics will be valid regardless of any correlation between the SNPs.  
A SNP was considered to be significantly associated with prostate cancer risk if the nominal p-
value and the permuted p-value were both less than 0.05.  In the results section, we report 
unadjusted p-values. 
Haplotype analyses were performed using HPlus (http://qge.fhcrc.org/hplus/).  The 
primary endpoint for the survival analyses was time to death from prostate cancer.  Survival time, 
i.e., time elapsed from diagnosis until death, was the time dependent variable used.  In each case, 
a death certificate was obtained to confirm the event.  Living cases were censored as of 
November 15th, 2007.  The association between survival and FGFR4 genotype was evaluated 
using Kaplan-Meier estimator functions and Cox’s proportional hazard models (25) to estimate 
hazard ratios (HR) and 95% confidence intervals (CI).  Final survival analysis models were 
adjusted for age at diagnosis, Gleason score and diagnostic PSA value. 
 
Results 
The characteristics of the 1458 prostate cancer cases and 1352 controls enrolled in this study are 
portrayed in Table 1.  By design, cases and controls did not differ significantly by race or age.    
Due to the low number of African Americans recruited to this study, analyses of these men were 
restricted to logistic regression only.  The genotypic frequencies of the four FGFR4 SNPs did not 
deviate significantly from Hardy-Weinberg equilibrium in the control samples nor was there 
apparent linkage disequilibrium between the four SNPs. 
There was no significant evidence of an association between any of the FGFR4 SNPs 
whether investigated individually (Table 2) or in haplotypes (data not shown) and the risk of 
prostate cancer in Caucasian or African American men.  Similarly, evaluation of prostate cancer 
risk in Caucasians within categories defined by aggressiveness, Gleason score, or stage of 
disease in polytomous models did not yield significant results (data not shown). 
Subset analyses looking at only those cases that had undergone radical prostatectomy 
(57% of all cases) compared to controls showed associations between prostate cancer risk and 
SNPs rs351855, rs1966265 and rs7708357 under a dominant model (Table 3).  While the effects 
of the minor alleles of rs1966265 and rs7708357 were only of borderline significance in terms of 
disease risk (OR=0.82; 95% CI 0.7-0.99; OR=1.21; 95% CI 1.0-1.47 respectively), carriers of 
the minor T allele of rs351855 had a significant increase in prostate cancer risk (OR=1.34; 95% 
CI 1.11-1.62; p=0.002).  To further investigate the effect of rs351855, we performed polytomous 
analyses to examine whether it is associated with aggressive disease, Gleason score and/or tumor 
stage.  As presented in Table 4, the risk for prostate cancer did not differ significantly by disease 
aggressiveness, Gleason score or stage for carriers of the minor rs351855 T allele. 
Survival analyses were performed in the overall case dataset to evaluate prostate cancer-
specific survival in the presence of each of the FGFR4 SNP genotypes.  There was no decrease 
in prostate cancer-specific survival associated with SNPs rs1966265, rs376618 and rs7708357 
(data not shown).  However, cases with the C allele of rs351855 experienced a significantly 
worse cause-specific survival (Figure 1) relative to men with only T alleles, with a hazard ratio 
of 1.7 (95% CI, 1.01-2.92; p=0.04). 
 
Discussion 
Our study found no significant associations between any of the four FGFR4 tag SNPs and 
prostate cancer risk overall or when considering disease aggressiveness, Gleason score or tumor 
stage.  Cases with one or two copies of the Gly allele of rs351855 did, however, have somewhat 
lower prostate-specific survival.  In order to replicate the study design by Wang et al. (2004), we 
also analyzed only those patients who had undergone a radical prostatectomy compared to 
controls.  While risk did not differ significantly in terms of disease aggressiveness, Gleason score 
or stage, cases that had undergone radical prostatectomy as primary therapy and carried one or 
two copies of the rs351855 Arg allele had a greater risk of prostate cancer overall.  The 
significance of this observation in only the subset of cases treated with radical prostatectomy is 
not clear. 
FGFs and FGFRs have been associated with occurrence and prognoses in lung, bladder, 
cervical, breast, colorectal, and prostate cancers.  In lung adenocarcinoma, the presence of either 
one or two copies of the Arg allele at rs351855 was significantly associated with an earlier age of 
disease onset (median 60.2 years vs. 64.6 years for Gly/Gly genotype; p=0.009) (19).  The Arg 
allele was also associated with advanced clinical stage and more frequent lymph node metastases 
than the Gly/Gly genotype in lung cancer patients (20). 
There is also evidence that the interaction between FGF19 and FGFR4 contributes to 
progression in liver, lung, and colon tumors (26).  Specifically, blocking the interaction of 
FGF19 and FGFR4 inhibited tumor growth in colon xenografts and prevented hepatocellular 
carcinomas in FGF19 transgenic mice.  In addition, the FGFR4 Arg allele of rs351855 has been 
associated with early lymph node metastasis and advanced lymph node metastasis in colon 
cancer patients (17).  It is also implicated in reducing disease-free survival time and overall 
survival as well as attenuating the effects of adjuvant systemic therapy in colon cancer (17,21).  
In contrast to the effects of the Arg allele, in breast cancer the Gly allele of rs351855 appears to 
function as a tumor suppressor in tissue culture assays, suppressing the cell motility of invasive 
breast cancer cells (20).  However as compelling as these biological results are, subsequent case 
only and case-control studies have shown no epidemiological evidence for an association 
between the FGFR4 Gly388Arg mutation and the above mentioned cancers (18,27,28). 
However, in relation to prostate cancer, Wang et al. (2004) reported a significant 
association between the Arg allele and disease occurrence where 15% of radical prostatectomy 
cases carried the Arg/Arg genotype at codon 388 compared to only 4% of controls, (p=0.005) 
(16).  The Arg allele was also overrepresented in radical prostatectomy cases with lymph node 
metastases (p=0.04) and PSA recurrence (p=0.02).  To examine the biological effects of the two 
rs351855 alleles, Wang and colleagues (2004) established cell lines expressing either the Gly or 
Arg alleles using the prostate epithelial cell line PNT1A (17).  Cells expressing Gly grew in 
tightly connected colonies while Arg expressing cells grew in a more scattered, irregular 
morphology.  To investigate differences in cell motility, which when increased can contribute to 
metastatic disease, a wound assay was also performed (17).  At both 24 and 48 hours the cells 
expressing Gly alleles showed a slower closure rate than those expressing Arg alleles.  
Additionally, a Matrigel assay was used to confirm that the Arg expressing cells displayed higher 
invasiveness than their Gly expressing counterparts (17).  The increased motility and 
invasiveness seen in cells expressing Arg may be attributed to the associated increase in uPAR, 
part of the urokinase activator system suggested to be involved in invasion and metastasis of 
prostate (29) and other cancers (30).  Whilst we also observe a significant association between 
disease risk and the rs351855 Arg allele in radical prostatectomy cases, this association is not 
observed at the population-based level or when considering disease aggressiveness, Gleason 
score or tumor stage. 
There are a number of strengths and limitations that should be considered when 
interpreting our results.  Our study has a much larger sample size than previous studies of 
FGFR4 SNP genotypes and prostate cancer risk (13,15,16).  Follow-up studies in other types of 
cancer have also experienced difficulty in replicating results derived from small datasets when 
larger sample sizes are considered (18,27,28).  In addition, the data presented here are 
population-based and thus reflect the disease as it presents in the general population.  However a 
limitation of this study is the small numbers of African American men present in the population 
of Western Washington.   Also, the limited number of prostate cancer-specific deaths in this 
population reduces power for the survival analyses.  Finally, although the FGFR4 tag SNPs 
distinguish all six haplotypes that occur in the Caucasian HapMap LD block, we cannot rule out 
possible associations that may exist between other SNPs in or near the FGFR4 gene and prostate 
cancer. 
The findings of this study do not support a major role of FGFR4 in relation to prostate 
cancer risk overall or among patients with more aggressive disease, higher Gleason score or 
advanced tumor stage.  There was a weak association between the Gly388Arg SNP and worse 
prostate cancer-specific survival as well as prostate cancer risk among men who underwent a 
radical prostatectomy; however, the effect of the former is small and the significance of the latter 
is unclear.    
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Table 1    Demographic and clinicopathologic characteristics of the population-based study 
participants, King County, Washington 
Characteristic Cases N=1,458 (%) Controls N=1,352 (%) 
Race   
    African American 149 (10.2) 85 (6.3) 
    Caucasian 1309 (89.8) 1267 (93.7) 
Age   
    35 - 49 118 (8.1) 127 (9.4) 
    50 - 54 214 (14.7) 209 (15.5) 
    55 - 59 357 (24.5) 358 (26.5) 
    60 - 64 433 (29.7) 348 (25.7) 
    65 - 69 177 (12.2) 164 (12.1) 
    70 - 74 158 (10.8) 146 (10.8) 
First-degree Family History of PC   
    No 1144 (78.5) 1200 (88.8) 
    Yes 313 (21.5) 152 (11.2) 
PC Screening History   
    Never 157 (10.8) 183 (13.5) 
    DRE only 257 (17.6) 519 (38.4) 
    PSA +/- DRE 1043 (71.6) 650 (48.1) 
Aggressiveness of  Disease   
    Less Aggressive 975 (66.9) - 
    More Aggressive 482 (33.1) - 
Gleason Grade   
    ≤7 (3+4) 1221 (84.2) - 
    ≥7 (4+3)  230 (15.8) - 
Tumor Stage   
    Local 1132 (78.2) - 
    Regional/Distant 315 (21.3) - 
Radical Prostatectomy as Primary 
Treatment   
    No 626 (43) - 
    Yes 831 (57) - 
Abbreviations: PSA, prostate-specific antigen; DRE, digital rectal examination. 
 
 
Table 2    Association between FGFR4 genotypes and prostate cancer risk by race 
SNP, Genotype Cases (%) Controls (%) OR (95% CI) P-value1
Caucasians     
rs1966265     
    GG 782 (62.1) 742 (59.2) Reference 0.18 
    AG 405 (32.2) 447 (35.6) 0.86 (0.73 - 1.02)  
    AA 72 (5.7) 65 (5.2) 1.05 (0.74 - 1.49)  
rs376618     
    AA 703 (56.8) 712 (57.2) Reference 0.73 
    AG 448 (36.2) 437 (35.1) 1.04 (0.88 - 1.23)  
    GG 87 (7) 96 (7.7) 0.92 (0.67 - 1.25)  
rs351855     
    CC 587 (46.8) 631 (50.4) Reference 0.15 
    CT 544 (43.4) 496 (39.1) 1.18 (0.99 - 1.39)  
    TT 123 (9.8) 124 (9.9) 1.06 (0.80 - 1.39  
rs7708357     
    GG 459 (36.5) 507 (40.4) Reference 0.05 
    AG 632 (50.2) 569 (45.4) 1.23 (1.04 - 1.46)  
    AA 167 (13.3) 178 (14.2) 1.03 (0.81 - 1.32)  
African Americans     
rs1966265     
    GG 132 (89.8) 70 (87.5) Reference 0.57 
    AG 15 (10.2) 10 (12.5) 0.77 (0.31 - 1.93)  
rs376618     
    AA 65 (44.8) 38 (47.5) Reference 0.25 
    AG 59 (40.7) 38 (47.5) 0.96 (0.52 - 1.75)  
    GG 21 (14.5) 4 (5) 2.46 (0.81 - 9.28)  
rs351855     
    CC 104 (71.2) 60 (75) Reference 0.40 
    CT 39 (26.7) 18 (22.5) 1.29 (0.66 - 2.59)  
    TT 3 (2.1) 2 (2.5) 0.34 (0.05 - 2.86)  
rs7708357     
    AA 23 (15.8) 9 (11.5) Reference 0.38 
    AG 74 (50.7) 35 (44.9) 0.89 (0.34 - 2.18)  
    GG 49 (33.6) 34 (43.6) 0.60 (0.23 - 1.50)  
Abbreviations: CI, confidence interval; FGFR4, fibroblast growth factor receptor 4; OR, odds ratio; SNP, single 
nucleotide polymorphism. 
aIndicates P-values that are significant at the 0.05 level after adjusting for multiple comparisons.
Table 3    Association between FGFR4 genotypes and prostate cancer risk in Caucasian cases who 
had radical prostatectomy as primary treatment compared to controls 
SNP, Genotype Cases (%) Controls (%) OR (95% CI) P-value1
rs1966265     
    GG  470 (63.7) 742 (59.2) Reference 0.04 
    AG±AA 268 (36.3) 512 (40.8) 0.82 (0.68 - 0.99)  
rs376618     
    AA 404 (56) 712 (57.2) Reference 0.72 
    AG±GG 317 (44) 533 (42.8) 1.04 (0.86 - 1.23)  
rs351855     
    CC 321 (43.8) 631 (50.44) Reference 0.002a
    CT±TT 411 (56.2) 620 (49.6) 1.34 (1.11 - 1.62)  
rs7708357     
    GG 263 (35.7) 507 (40.4) Reference 0.05 
    AG±AA 474 (64.3) 747 (59.6) 1.21 (1.00 - 1.47)  
Abbreviations: CI, confidence interval; FGFR4, fibroblast growth factor receptor 4; OR, odds ratio; SNP, single 
nucleotide polymorphism. 
aIndicates P-values that are significant at the 0.05 level after adjusting for multiple comparisons.
 
Table 4    Association between FGFR4 rs351855 genotype and risk of prostate cancer in Caucasian cases who had radical prostatectomy 
as primary therapy, stratified by clinical features, compared to controls 
rs351855 Controls Cases, Less Aggressive Cases, More Aggressive p-valuea
Genotype N (%) N (%) OR 95% C I N (%) OR 95% CI  
    CC 631 (50.4) 199 (43.5) 1 Reference 122 (44.4) 1 Reference  
CT±TT 620 (49.6) 258 (56.5) 1.36 1.10 – 1.70 153 (55.6) 1.31 1.00 – 1.70 0.78 
         
  Cases, Gleason Score ≤ 7 (3+4) Cases, Gleason Score ≥ 7 (4+3)  
  N (%) OR 95% C I N (%) OR 95% CI  
    CC 631 (50.4) 281 (44.4) 1 Reference 40 (40.4) 1 Reference  
CT±TT 620 (49.6) 352 (55.6) 1.32 1.08 – 1.60 59 (59.6) 1.50 0.99 – 2.28 0.55 
         
  Cases, Local Stage Cases, Regional/Distant Stage  
  N (%) OR 95% C I N (%) OR 95% CI  
    CC 631 (50.4) 228 (43.8) 1 Reference 93 (44.1) 1 Reference  
CT±TT 620 (49.6) 293 (56.42 1.35 1.09 – 1.66 118 (55.9) 1.33 0.99 – 1.78 0.92 
Abbreviations: CI, confidence intervals; FGFR4, fibroblast growth factor receptor 4; OR, odds ratio; SNP, single nucleotide polymorphism. 
aTest for homogeneity of ORs across clinical features. 
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Figure 1 Kaplan-Meier survival estimates for Caucasian prostate cancer patients 
according to rs351855 genotype. 
 
